Cell production rates in human tissues and tumours and their significance. Part 1: An introduction to the techniques of measurement and their limitations

European Journal of Surgical Oncology

Volumn 26, Issue 3, 2000, Pages 227-238

  Rew, D A ^a   Wilson, G D ^b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b Group for Biostatistics in Oncology   (United Kingdom)

Author keywords

Bromodeoxyuridine; Cancer; Cell proliferation; Clinical outcome; Flow cytometry; Prognosis

Indexed keywords

BROXURIDINE; HALIDE; IDOXURIDINE; THYMIDINE;

BIOPSY; CALCULATION; CANCER THERAPY; CELL CYCLE S PHASE; CELL LABELING; CELL PROLIFERATION; CYTOMETRY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LABELING INDEX; LABORATORY; LASER; MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TECHNIQUE; TUMOR GROWTH;

EID: 0034109745     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.1999.0781     Document Type: Review

References (67)

1. 32P as demonstrated by autoradiographs. Exp Cell Res. 2:1951;178-187.
2. Laird AK. Dynamics of tumor growth. Br J Cancer. 18:1964;490-502.
3. Steel GG. Growth kinetics of tumors. Oxford, UK: Clarendon Press. 1977.
4. Frankfurt OS, Slokum HK, Rustum YM. Flow cytometric analysis of DNA aneuploidy in primary and metastatic human solid tumours. Cytometry. 5:1984;71-80.
5. Frankfurt OS, Arbuck SG, Chin JL, Greco WR. Prognostic applications of DNA flow cytometry for human solid tumours. Annals NYAS. 468:1986;276-290.
6. Hedley DW. Flow cytometry using paraffin-embedded tissue. Five years on. Cytometry. 10:1989;229-241.
7. Tubiana M, Courdi A. Cell proliferation kinetics in human solid tumors; relation to probability of metastatic dissemination and long term survival. Radiother Oncol. 15:1989;1-18.
8. Quinn CM, Wright NA. Review Article: The clinical assessment of proliferation and growth in human tumours: Evaluation of methods and applications as prognostic variables. J Pathol. 160:1990;93-102.
9. Hall PA, Levison DA, Woods AL. Proliferating cell nuclear antigen localisation in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol. 162:1990;285-294.
10. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody relative with a human nuclear antigen associated with cell proliferation. Br J Cancer. 31:1983;13-20.
11. Darzynkiewicz Z, Gong J, Juan G, Ardelt B, Traganos F. Cytometry of cyclin proteins. Cytometry. 25:1996;1-13.
12. Taylor JH, Woods PS, Hughes WL. The organization and duplication of chromosomes using tritium-labeled thymidine. Proc Soc Natl Acad Sci USA. 43:1957;122-128.
13. Quastler H, Sherman FG. Cell population kinetics in the intestinal epithelium of the mouse. Exp Cell Res. 17:1959;420-428.
14. Wright NA, Britton DR, Bone G, Appleton DR. Cell proliferation in gastric carcinoma. A stathmokinetic study. Cell Tissue Kinet. 10:1977;429-438.
15. Camplejohn RS. Cell kinetics of colorectal tumours. Recent results. Cancer Res. 83:1982;21-30.
16. Dolbeare F. Bromodeoxyuridine: a diagnostic tool in biology and medicine. Part I: Historical perspectives, histochemical methods and cell kinetics [Review]. Histochem J. 27:1995;339-369.
17. Begg AC, Moonen L, Hofland I, Dessing M, Bartelink H. Human tumor kinetics using a monoclonal antibody against iododeoxyuridine. Intra-tumor sampling variations. Radiother Oncol. 11:1988;337-347.
18. Gratzner HG. Monoclonal antibody to 5-bromo and 5-iodo deoxyuridine: a new reagent for detection of DNA replication. Science. 218:1982;474-475.
19. Gray JW. Monoclonal antibodies against bromodeoxyuridine. Editor. Cytometry. 6:1985;499-662.
20. Vanderlaan M, Thomas CB. Characterization of monoclonal antibodies to bromodeoxyuridine. Cytometry. 6:1985;501-505.
21. Gonchoroff NJ, Greipp PR, Kyle RA, Katzmann JA. A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation. Cytometry. 6:1985;506-512.
22. Beisker W, Dolbeare F, Gray JW. An improved immunocyto-chemical procedure for high sensitivity detection of incorporated BrdUrd. Cytometry. 8:1987;235-239.
23. Sasaki K, Ogino T, Takahashi M. Immunological determination of labeling index on human tumor tissue sections using monoclonal anti-BrdUrd antibody. Stain Technol. 61:1986;155-161.
24. Nishizaki T, Orita T, Saiki M, Furutani Y, Aoki H. Cell kinetics studies of human brain tumors by in vitro labeling using anti-BUdR monoclonal antibody. J Neurosurg. 69:1988;371-374.
25. Dolbeare F, Gratzner H, Pallavicini M, Gray JW. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci USA. 80:1983;5573-5577.
26. Dolbeare F, Beisker W, Pallavicini MG, Vanderlaan M, Gray JW. Cyto-chemistry for BrdUrd/DNA analysis. Stoichiometry and sensitivity. Cytometry. 6:1985;521-530.
27. Waldman FM, Dolbeare F, Gray J. Clinical applications of the bromodeoxyuridine/DNA assay. Cytometry. 5 (Suppl. 3):1988;65-72.
28. Kamentsky LA, Kamentsky LD. Microscope based multiparameter laser scanning cytometer which yields data comparable to flow cytometry data. Cytometry. 12:1991;381-387.
29. Rew DA, Reeve L, Wilson GD. A comparison of flow and laser scanning cytometry in the study of bromodeoxyuridine derived proliferation parameters in human tumours. Cytometry. 1998: in press.
30. Barrett JC, Tsutsui T, Ts'o POP. Neoplastic transformation induced by a direct perturbation of DNA. Nature. 274:1978;229-232.
31. Kaufman ER. Altered CTP synthetase activity confers resistance to 5-bromodeoxyuridine toxicity and mutagenesis. Mutat Res. 161:1986;19-27.
32. Raffel C, Deen DF, Edwards MS. Bromodeoxyuridine: a comparison of its photo-sensitizing and radiosensitizing properties. J Neurosurg. 69:1988;410-415.
33. Kinsella TJ, Mitchell JB, Russo A, Aiken M, Morstyn G, Hsu SM, Rowland J, Glatstein E. Continuous intravenous infusions of bromodeoxyuridine as a clinical radiosensitizer. J Clin Oncol. 2:1984;1144-1150.
34. Speth PA, Kinsella T, Chang A, Klecker R, Belanger K, Smith R, Rowland J, Cupp J, Collins JM. Iododeoxyuridine incorporation into human haematopoeitic cells, normal liver and hepatic metastases in man as a radiosensitiser and as a marker for cell kinetic studies. Int J Radiat Oncol Biol Phys. 16:1989;1247-1250.
35. Fine JD, Breathnach SM. Distinctive eruption characterised by linear supravenous papules and erythroderma following bromoxuridine therapy and radiotherapy. Arch Dermatol. 122:1986;199-200.
36. Lloveras B, Garin-Chesa P, Myc A, Melamed M. In vitro bromodeoxyuridine labelling of malignant neoplasms. A comparative study with flow cytometry cell-cycle analysis. Am J Clin Pathol. 101:1994;703-707.
37. Miwa H, Wada R, Abe H, Ohkura R, Yang SW, Watanabe H, Ogihara T, Hamada T, Sato N. Diagnosis of gastric adenoma versus early gastric cancer by bromodeoxyuridine immunohistochemistry from gastric biopsy specimen. J Gastroenterol Hepatol. 8:1993;133-137.
38. Kang SM, Kim WH, Kim CW, Kim YI. Comparison of bromodeoxyuridine and proliferating cell nuclear antigen labeling in gastric carcinoma. J Korean Med Sci. 9:1994;16-20.
39. Tachibana M, Miyakawa A, Nakamura K, Baba S, Murai M, Tazaki H. Role of proliferative activity estimated by BrdUrd labeling index in determining predictive factors of recurrence in superficial intermediately malignant bladder tumors. J Urol. 156:1996;63-69.
40. Meyer JS, Nauert J, Koehm S, Hughes J. Cell kinetics of human tumours by in vitro bromodeoxyuridine labeling. J Histochem Cytochem. 37:1989;1449-1454.
41. Meyer JS, Koehm SL, Hughes JM, Higa E, Wittliff JL, Lagos JA, Manes JL. Bromodeoxyuridine labeling for S-phase measurement in breast carcinoma. Cancer. 71:1993;3531-3540.
42. Wilson GD, McNally NJ, Dunphy E, Karcher H, Pfragner R. The labelling index of human and mouse tumors assessed by BrdUrd staining in vitro and in vivo and flow cytometry. Cytometry. 6:1985;641-647.
43. Hoshino T, Nagashima T, Murovic J, Levin E, Levin V, Rupp S. Cell kinetic studies of in situ human brain tumors using bromodeoxyuridine. Cytometry. 6:1985;627-633.
44. Raza A, Ucar K, Preisler HD. Double labeling and in vitro versus in vivo incorporation of BrdUrd in patients with acute nonlymphocytic leukemia. Cytometry. 6:1985;633-641.
45. Hoshino T, Prados M, Wilson CB, Cho KG, Lee KS, Davis RL. Prognostic implications of the bromodeoxyuridine labeling index of human gliomas. J Neurosurg. 71:1989;335-341.
46. Tinnemans MM, Lenders MH, ten Velde GP, Wagenaar SS, Blijham GH, Ramaekers FC, Schutte B. Evaluation of proliferation parameters in in vivo BrdUrd labeled lung cancers. Virchows Archiv. 427:1995;295-301.
47. Langford LA, Cooksley CS, DeMonte F. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. Hum Pathol. 27:1996;350-354.
48. Popert RJ, Joyce AD, Thomas DJ, Walmsley BH, Coptcoat MJ. Bromodeoxyuridine labeling of transitional cell carcinoma of the bladder - an index of recurrence? Br J Urol. 71:1993;279-283.
49. Larsson P, Roos G, Stenling R, Ljungberg B. Proliferation of human renal cell carcinoma studied with in vivo iododeoxyuridine labeling and immunohistochemistry. Scand J Urol Nephrol. 28:1994;135-140.
50. Kotelnikov VM, Coon JS, Taylor S, Hutchinson J, Panje W, Caldarelli DD, LaFollette S, Preisler HD. In vivo labeling with halogenated pyrimidines of squamous cell carcinomas and adjacent non-involved mucosa of head and neck region. Cell Proliferation. 28:1995;497-509.
51. Goodson WH, Ljung BM, Moore DH, Mayall B, Waldman FM, Chew K, Benz CC, Smith HS. Tumor labeling indices of primary breast cancers and their regional lymph node metastases. Cancer. 71:1993;3914-3919.
52. Christov K, Chew KL, Ljung BM, Waldman FM, Goodson WH 3rd, Smith HS, Mayall BH. Cell proliferation in hyperplastic and in situ carcinoma lesions of the breast estimated by in vivo labeling with bromodeoxyuridine. J Cellular Biochem. Suppl. 19:1994;165-172.
53. Maas RA, Bruning PF, Breedijk AJ, Peterse JL. Iododeoxyuridine labeling of S-phase fraction in fine needle aspirates from breast carcinomas. J Clin Pathol. 49:1996;607-609.
54. Begg AC, McNally NJ, Shrieve DC, Karcher H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry. 6:1985;620-626.
55. Wilson GD, McNally NJ, Rische S, Saunders MI, Des Rochers C, Lewis AA, Bennett MH. Measurement of cell kinetics in human tumors in vivo using bromodeoxy-uridine incorporation and flow cytometry. Br J Cancer. 58:1988;423-431.
56. Riccardi A, Danova M, Wilson GD, Ucci G, Dormer P, Mazzini G, Brugnatelli S, Girino M, McNally N, Ascari E. Cell kinetics in human malignancies studied with in vivo administration of bromodeoxyuridine and flow cytometry. Cancer Res. 48:1988;6238-6245.
57. Begg AC. Derivation of cell kinetic parameters from human tumours after labelling with bromodeoxyuridine or iododeoxyuridine. Br Inst Radiology Report. 19:1989;113-119.
58. Terry NH, White RA, Meistrich ML, Calkins DP. Evaluation of flow cytometric methods for determining population potential doubling times using cultured cells. Cytometry. 12:1991;234-241.
59. Rew DA, Wilson GD. Advances in cell kinetics: A leading article. BMJ. 303:1991;532-533.
60. Rew DA. Heterogeneity, biodiversity and bioperversity in solid neoplasms. Eur J Surg Oncol. 22:1996;469-473.
61. Bennett MH, Wilson GD, Dische S, Saunders MI, Martindale CA, Robinson BM, O'Halloran AE, Leslie MD, Laing JHE. Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck. Br J Cancer. 65:1992;870-878.
62. Rew DA. Cell proliferation, tumor growth and clinical outcome: gains and losses in intestinal cancer. Ann Roy Coll Surg Eng. 75:1993;397-404.
63. Wilson GD. Limitations of the BUdR technique for measurement of tumour proliferation. In: Beck-Bornholdt HP (ed.) Current Topics in Clinical Radiobiology of Tumors: Medical Radiology. Berlin: Springer-Verlag. 1993.
64. Haustermans K, Hofland I, Pottie G, Ramaekers M, Begg AC. Can measurements of potential doubling time (Tpot) be compared between laboratories? A quality control study. Cytometry. 19:1995;154-163.
65. Williamson KE, Gilliland R, Weir H, Grimes J, Hamilton P, Anderson N, Crockard A, Rowlands B. Hydrochloric acid denaturation of colorectal tumour tissue infiltrated with bromodeoxyuridine. Cytometry. 15:1994;162-168.
66. Gilliland R, Williamson KE, Hamilton P, Crockard A, Spence RA. DNA denaturation sensitivity may invalidate bromodeoxyuridine-DNA flow cytometric analysis of the potential doubling time in colorectal tumours. Br J Surg. 84:1997;242-247.
67. Shibui S, Hoshino T, Vanderlaan M, Gray JW. Double labelling with iodo- and bromodeoxyuridine for cell kinetics studies. J Histochem Cytochem. 37:1989;1007-1011.